ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
5,670.97
0.67%
US Tech 100
18,443.20
-2.46%
다우존스 지수
42,225.32
0.56%
Bitcoin
85,659.98
0.57%
Registration Strip Icon for charts 실시간 차트, 분석 도구 및 가격을 받으려면 등록하세요.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 미국
  5. NASDAQ

  6. Astria Therapeutics Inc (ATXS) 시세

Astria Therapeutics Inc

Astria Therapeutics Inc (ATXS)

NASDAQ
5.52
0.12
(2.22%)
종가: 03 4월 5:00AM
15분 지연
5.52
0.00
( 0.00% )
시간외 거래: 5:36AM
15분 지연

포트폴리오 강화: 실시간 토론 및 실행 가능한 거래 아이디어.

프리미엄

주요 통계 및 세부정보

가격
5.52
매수가
2.24
매도가
6.58
거래량
243,871
5.33 일간 변동폭 5.60
5.24 52주 범위 13.04
market_cap
311.517M
전일 종가
5.40
개장가
5.33
최근 거래 시간
4
@
5.52
마지막 거래 시간
05:12:59
재정 규모
US$ 1,335,206
VWAP
5.475
평균 볼륨(3m)
274,783
발행 주식
56,434,219
배당수익률
-
주가수익률
-6.61
주당순이익(EPS)
-1.29
매출
-
순이익
-72.89M

Astria Therapeutics Inc 정보

Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for... Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. 더 보기

섹터
Pharmaceutical Preparations
산업
Pharmaceutical Preparations
웹사이트
www.astriatx.com
본부
Wilmington, Delaware, USA
설립됨
-
Astria Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the 나스닥 with ticker ATXS. The last closing price for Astria Therapeutics was US$5.40. Over the last year, Astria Therapeutics shares have traded in a share price range of US$ 5.24 to US$ 13.04.

Astria Therapeutics currently has 56,434,219 shares in issue. The market capitalisation of Astria Therapeutics is US$304.74 million. Astria Therapeutics has a price to earnings ratio (PE ratio) of -6.61.

ATXS 최신 뉴스

추가 뉴스

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
26 3월 2025
ATXS (2.22%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
26 3월 2025
ATXS (2.22%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
26 3월 2025
ATXS (2.22%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
26 3월 2025
ATXS (2.22%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
26 3월 2025
ATXS (2.22%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
26 3월 2025
ATXS (2.22%)

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Edgar (US Regulatory)
12 3월 2025
ATXS (2.22%)

Form 8-K - Current report
Edgar (US Regulatory)
11 3월 2025
ATXS (2.22%)
기간변동변동 %시가고가저가평균 일일 거래량VWAP
1-0.74-11.8210862626.266.265.242798425.60395654CS
4-0.595-9.730171708916.1157.295.242933516.24575324CS
12-3.12-36.11111111118.648.645.242747836.85869258CS
26-5.7-50.802139037411.2212.5155.242805898.76786627CS
52-7.48-57.53846153851313.045.244005929.79737723CS
156-0.98-15.07692307696.516.92.3633680910.2934987CS
260-3.01-35.28722157098.5316.92.3629142810.19143436CS

ATXS - Frequently Asked Questions (FAQ)

What is the current Astria Therapeutics share price?
The current share price of Astria Therapeutics is US$ 5.52
How many Astria Therapeutics shares are in issue?
Astria Therapeutics has 56,434,219 shares in issue
What is the market cap of Astria Therapeutics?
The market capitalisation of Astria Therapeutics is USD 304.74M
What is the 1 year trading range for Astria Therapeutics share price?
Astria Therapeutics has traded in the range of US$ 5.24 to US$ 13.04 during the past year
What is the PE ratio of Astria Therapeutics?
The price to earnings ratio of Astria Therapeutics is -6.61
What is the reporting currency for Astria Therapeutics?
Astria Therapeutics reports financial results in USD
What is the latest annual profit for Astria Therapeutics?
The latest annual profit of Astria Therapeutics is USD -72.89M
What is the registered address of Astria Therapeutics?
The registered address for Astria Therapeutics is 1209 ORANGE STREET, WILMINGTON, DELAWARE, 19801
What is the Astria Therapeutics website address?
The website address for Astria Therapeutics is www.astriatx.com
Which industry sector does Astria Therapeutics operate in?
Astria Therapeutics operates in the PHARMACEUTICAL PREPARATIONS sector

이동자

모두 보기
  • 가장 활성
  • % 상승자
  • % 패자
기호가격볼륨
PTIXProtagenic Therapeutics Inc
US$ 0.5708
(151.45%)
7.56M
GNPXGenprex Inc
US$ 0.367
(24.41%)
14.81M
DMNDamon Inc
US$ 0.0155
(12.32%)
16.24M
SWAGStran and Company Inc
US$ 1.08
(11.34%)
712
STSSSharps Technology Inc
US$ 0.033
(11.11%)
17.72M
BIAFbioAffinity Technologies Inc
US$ 0.64
(-28.09%)
1.1M
AREBAmerican Rebel Holdings Inc
US$ 4.76
(-24.32%)
1.24M
LGCBLinkage Global Inc
US$ 0.1301
(-17.57%)
98.4k
VRPXVirpax Pharmaceuticals Inc
US$ 1.08
(-11.48%)
15.45k
HOURHour Loop Inc
US$ 1.30
(-10.34%)
1.93k
TSLLDirexion Daily TSLA Bull 2X Trust ETF
US$ 10.5701
(-6.21%)
18.89M
STSSSharps Technology Inc
US$ 0.033
(11.11%)
17.72M
DMNDamon Inc
US$ 0.0155
(12.32%)
16.24M
GNPXGenprex Inc
US$ 0.367
(24.41%)
14.81M
LCIDLucid Group Inc
US$ 2.39
(-0.42%)
9.26M

ATXS Discussion

게시물 보기
Monksdream Monksdream 7 월 전
ATXS under $15
👍️0
Monksdream Monksdream 9 월 전
ATXS under $10
👍️0
Monksdream Monksdream 11 월 전
ATXS under $10
👍️0
GreenStockEVs GreenStockEVs 2 년 전
NEWS OUT - Astria Therapeutics Receives Fast Track Designation for STAR-0215 for the Treatment of Hereditary Angioedema

About Astria Therapeutics:

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development for the treatment of hereditary angioedema. Learn more about our company on our website, www.astriatx.com.
👍️0

최근 히스토리

NASDAQ
ATXS
Astria Therapeutics
AMEX
IWF
iShares Russell 1000 Gro...
LSE
0IRK
Altarea Sca
NASDAQ
CEFDX
Ci Global Resource Fund ...
NASDAQ
CCQKX
Ci Diversified Yield Cor...
COIN
BRICKKUSD
r/FortNiteBR Bricks
NASDAQ
CCNQX
Ci Corporate Bond Class ...
NASDAQ
CBVSX
Ci Canadian Dividend Cor...
TSX
AVNT
Avant Brands
DGFX
CRUUSDT
CRUST
AQSE
AIGP.GB
WT Precious Metals
CRTO
GASUSD
NEO Gas
BIT
NSCIT0012434
Danone
BIT
NSCIT1139319
Total Capital
BIT
NSCIT6848609
Credito Emiliano
BIT
NSCIT0112739
Republic of Poland
Delayed Upgrade Clock
ADVFN Logo
대한민국
회사 소개
사업
Popular
앱 받기
App Store
Google Play

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2025 ADVFN PLC - 모든 권리 보유

광고 제거

광고 없는 경험을 위해 가입하세요

광고 없음

지금 사용해 보세요

광고 유지